The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosacharride in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

The present invention provides amidic polymers, which exhibit shale swelling inhibitor activity having improved bio-degradability. The amidic polymers of the invention may be employed in a wide variety of compositions, particularly in subterranean drilling operations. Non-limiting generic structures of the amidic polymers are set out below: (1) wherein R.sub.1-R.sub.3 and integers m and n are defined herein.

##STR00001##

A composition contains a silylated polysaccharide, where the silylated polysaccharide is characterized by: (a) having linked fructose, galactose, anhydrogalactose, or glucose saccharide units provided that glycosidic linkages of glucose are alpha linkages and that the silylated polysaccharide is other than a silylated starch; and (b) on average 1 to 100 mole-percent of the hydroxyl groups on the polysaccharide have been silylated with a silyl group having the structure SiR.sub.3 linked to the polysaccharide through a COSi bond where each R is independently selected from hydrocarbyl radicals having from one to 12 carbon atoms, provided that on average at least one R per polysaccharide has a terminally unsaturated carbon-carbon double bond.

Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt % glucose linked at positions 1 and 6; (ii) 0.1-1.2 wt % glucose linked at positions 1 and 3; (iii) 0.1-0.7 wt % glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt % glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt % glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles. Further disclosed are methods of using compositions comprising dextran, such as increasing the viscosity of an aqueous composition. Enzymatic reactions for producing dextran are also disclosed.

The invention is directed to stabilizing functionalized polymers and compositions containing polysaccharides and polysaccharide derivatives functionalized with amine, alkyl and/or alkyl/amine moieties, and methods for reducing swelling of soils and especially clay-containing soils with stabilization functionalized polymers and compositions of the invention.

A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more dextran molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more dextran molecules are covalently grafted to the cross-linked hyaluronic acid.

The invention relates to peptide conjugates that can bind to endothelial cells, and that are useful for reducing the incidence and severity of endothelial dysfunction in mammals.

The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by irradiation an electron beam to an aqueous solution comprising at least one substance selected from the group consisting of a polysaccharide, a derivative thereof and a polyethylene glycol, thereby inducing inter-molecular cross-linking or intra-molecular cross-linking, and to a use of the biocompatible nanoparticle in a drug carrier, a contrast agent, a diagnostic agent or an intestinal adhesion prevention agent or for disease prevention and treatment.

A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.

The growth and/or proliferation of mammalian cells are modulated by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. Sulfated polysaccharides, preferably glycosaminoglycans, can be used as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation. The physical interaction between platelets (thrombocytes) and the surface of the cells can be modulated in vitro in order to modulate cell proliferation. Inhibition of the interaction between the cell surface and platelets can inhibit cell growth, and enhancement of the interaction between platelets and the surface of the cell can enhance cell growth.